Citigroup Downgrades Mersana Therapeutics to Neutral, Lowers Price Target to $1
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Ashik Kurian has downgraded Mersana Therapeutics from Buy to Neutral and lowered the price target from $10 to $1.
July 28, 2023 | 1:18 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Mersana Therapeutics has been downgraded by Citigroup from Buy to Neutral, with a significant reduction in price target from $10 to $1.
The downgrade from Buy to Neutral by Citigroup, a major financial institution, coupled with a drastic reduction in price target, indicates a negative outlook for Mersana Therapeutics. This could potentially lead to a decrease in the stock's price in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100